摘要
[目的]评价紫杉醇联合化疗治疗晚期、复发子宫内膜癌的近期疗效及毒副作用.[方法]25例Ⅲ、Ⅳ期或复发的子宫内膜癌行紫杉醇+卡铂(或顺铂)化疗,紫杉醇135mg/m2～150mg/m2,卡铂AUC 4～5,或顺铂70mg/m2.[结果]有可测肿瘤或CA125/CA199升高16例,共进行63个疗程化疗,完全缓解37.5%,部分缓解25.0%,总有效率62.5%.完全缓解者无进展期平均5.3个月.无肿瘤监测指标9例,进行29个疗程化疗,中数随诊11.5个月无复发.3、4级白细胞下降40.0%,3级血小板下降11.4%.[结论]紫杉醇+卡铂或顺铂联合化疗对晚期、复发的子宫内膜癌有较好疗效.
To determine the efficacy and toxicity of paclitaxel in advanced or recurrent adenocarcinoma of the endometrium.Twenty-five patients with advanced or recurrent endometrial cancer were treated with pacli-taxel135mg/m 2 or150mg/m 2 over3hours and carboplatin AUC4~5or cisplatin70mg/m 2 .Sixteen cases with measurable disease or elevated received a total of63courses chemotherapy CA125/CA199.The overall response rate was62.5%with complete response37.5%and partial response25.0%.Median progression-free interval in patients of com-plete responses was5.3months.Severe(grade3or4)leukopenia or thrombocytopenia was40.0%and11.4%respec-tively.[Conclusion]This regimen of paclitaxel and carboplatin or cisplatin are active in patients with advanced or re-current adenocarcinoma of the endometrium.
出处
《肿瘤学杂志》
CAS
2004年第2期69-71,共3页
Journal of Chinese Oncology
关键词
紫杉醇
卡铂
子宫内膜癌
药物疗法
paclitaxel
carboplatin
adenocarcinoma of endometrium
drug therapy
